Pteropure (Pterostilbene)

Pterostilbene is a naturally occurring stilbenoid compound found in blueberries that demonstrates potential cardiovascular and anti-cancer effects. This dimethylated analog of resveratrol shows superior bioavailability and may influence cholesterol metabolism and cellular signaling pathways.

Origin & History

Pterostilbene is a natural stilbenoid compound and dimethylated derivative of resveratrol, found primarily in blueberries and the heartwood of Pterocarpus marsupium, a tree native to India. It is typically extracted from these plant sources to create pterostilbene-rich extracts, with Pteropure being a branded form of this compound.

Historical & Cultural Context

While pterostilbene-rich extracts from Pterocarpus marsupium heartwood have been evaluated in modern trials, specific traditional medicine systems or historical uses were not documented in the clinical sources. The compound's presence in blueberries is noted, but traditional use documentation is lacking.

Health Benefits

• May support healthy cholesterol levels, though one RCT (n=80) showed increased LDL cholesterol alongside reduced blood pressure (moderate evidence from NCT01267227)
• Demonstrates potential anti-cancer properties, with a phase II trial (n=37) showing suppression of pro-tumorigenic pathways in endometrial cancer when combined with megestrol acetate (preliminary clinical evidence)
• Exhibits anti-inflammatory effects through inhibition of NF-κB and PI3K/Akt signaling pathways (primarily preclinical evidence)
• Shows promising neuroprotective potential for cognitive support based on animal models (preclinical evidence only)
• Offers superior bioavailability (80%) compared to resveratrol (20%), allowing for better tissue distribution (pharmacokinetic studies)

How It Works

Pterostilbene activates sirtuins (SIRT1) and peroxisome proliferator-activated receptors (PPARα), influencing cellular metabolism and longevity pathways. The compound modulates HMG-CoA reductase activity, affecting cholesterol synthesis, while also inhibiting NF-κB signaling to reduce inflammatory responses. Its dimethoxy structure provides enhanced cellular uptake and metabolic stability compared to resveratrol.

Scientific Research

Clinical evidence includes a randomized, double-blind, placebo-controlled trial (n=80) testing pterostilbene safety over 6-8 weeks with no adverse effects on liver, kidney, or glucose markers (PMC3575612). A phase II trial in endometrial cancer (n=37, NCT03671811) showed pathway suppression with combination therapy. However, another RCT (NCT01267227, PMID: 25057276) reported increased LDL cholesterol despite blood pressure benefits.

Clinical Summary

A randomized controlled trial (NCT01267227) with 80 participants showed pterostilbene reduced systolic blood pressure by 7.8 mmHg but unexpectedly increased LDL cholesterol by 11 mg/dL at 250mg daily. A phase II cancer trial (n=37) demonstrated suppression of pro-tumorigenic pathways in endometrial tissue. Current clinical evidence is limited with mixed cardiovascular outcomes requiring further investigation. Most studies have used dosages between 125-250mg daily for 6-12 weeks.

Nutritional Profile

Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene) is a naturally occurring stilbenoid and dimethylated analog of resveratrol, with a molecular weight of 256.30 g/mol. It is not a macronutrient or traditional micronutrient source; it is classified as a bioactive polyphenolic compound. Key nutritional and pharmacological profile details: • Primary bioactive compound: Pterostilbene (typically standardized to ≥95–99% purity in commercial supplements such as Pteropure®, derived from Pterocarpus marsupium heartwood). • Typical supplement dosage: 50–250 mg per capsule; clinical trials have used 50 mg twice daily (100 mg/day) and 125 mg twice daily (250 mg/day). • Natural dietary sources: Found in small quantities in blueberries (~0.03–0.52 µg/g fresh weight), grapes (Vitis vinifera), almonds, and certain Pterocarpus species; dietary intake from food alone is negligible compared to supplemental doses. • Bioavailability: Significantly superior oral bioavailability (~80% in animal models) compared to resveratrol (~20%), attributed to the two methoxy groups replacing hydroxyl groups, which increases lipophilicity (logP ~3.0 vs ~1.6 for resveratrol), enhances membrane permeability, and reduces phase II conjugation (glucuronidation and sulfation). Plasma half-life in humans is estimated at ~2–4 hours. • Key metabolites: Pterostilbene-4'-O-glucuronide and pterostilbene-4'-O-sulfate are the primary circulating metabolites; some mono-demethylated metabolites (yielding pinostilbene and resveratrol-like structures) have also been detected. • Contains no significant macronutrients (protein, fat, carbohydrate, fiber) at supplemental doses. • Contains no vitamins or minerals. • Mechanism-relevant chemical features: The 3,5-dimethoxy substitution pattern confers enhanced metabolic stability and cellular uptake relative to polyhydroxylated stilbenes; it acts as an activator of SIRT1, PPAR-α, and AMPK signaling pathways and exhibits potent antioxidant activity (ORAC value substantially higher per mole than resveratrol in some in vitro assays). • Solubility: Poorly water-soluble (~24 µg/mL at 25°C); highly soluble in organic solvents (ethanol, DMSO); some formulations use cyclodextrin complexes or lipid-based delivery to enhance dissolution and absorption.

Preparation & Dosage

Clinically studied doses include 50 mg twice daily (low dose) or 125 mg twice daily (high dose), with some trials using 50 mg pterostilbene combined with 100 mg grape extract twice daily for 6-8 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Grape extract, resveratrol, quercetin, curcumin, omega-3 fatty acids

Safety & Interactions

Pterostilbene appears generally well-tolerated in clinical trials with minimal reported adverse effects. The compound may interact with cholesterol-lowering medications due to its effects on HMG-CoA reductase and lipid metabolism. Potential interactions with blood pressure medications should be monitored given its hypotensive effects. Safety during pregnancy and lactation has not been established, and individuals with bleeding disorders should exercise caution due to potential antiplatelet effects.